Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02
Carboplatino Teva 10 mg/ml Concentrado para solución para perfusiónSpiraxin 200 mg comprimidos recubiertos con películaIMFINZI 50 mg/mL concentrate for solution for infusionPaclitaxel Teva 6 mg/ml concentrado para solución para perfusión EFG
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
The primary objective is to evaluate the pathological Complete Response (pCR) rate in the intention to treat population (ITT population) Pathological Complete Response (pCR) defined as the absence of residual tumor in lung and lymph nodes after surgery.
Endpoint detail
1. Progression free survival (PFS) rate at 12 and 24 months, 2. Overall survival (OS) rate at 12 and 24 months of treatment, 3. Resectability rate (%), 4. Proportion of R0 resections (%), 5. Safety and tolerability of the treatment: Adverse events graded according to CTCAEv 5.0
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.